AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22944002 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined effect of DBS and l‐dopa administration
Number of subjects: 0
Study 22944002 — intervention group
Group type: COMPARATOR
Intervention: All treatment conditions combined
Number of subjects: 0
Study 20540847 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (2.5-10 mg/d)
Number of subjects: 65
Study 20540847 — intervention group
Group type: COMPARATOR
Intervention: Tiapride (25-400 mg/d)
Number of subjects: 65
Study 18400462 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based advanced home care (AHC)
Number of subjects: 0
Study 18400462 — intervention group
Group type: COMPARATOR
Intervention: Conventional care (CC)
Number of subjects: 0
Study 15667504 — intervention group
Group type: EXPERIMENTAL
Intervention: Naso-gastric (NG) feeding
Number of subjects: 50
Study 15667504 — intervention group
Group type: COMPARATOR
Intervention: Naso-jejunal (NJ) feeding
Number of subjects: 50
Study 15667504 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 50
Study 12046061 — intervention group
Group type: EXPERIMENTAL
Intervention: ZSP (Chinese herb composite)
Number of subjects: 0
Study 12046061 — intervention group
Group type: EXPERIMENTAL
Intervention: Riboflavin
Number of subjects: 0
Study 12046061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9931796 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmapheresis combined with continuous venovenous hemofiltration (CVVHF)
Number of subjects: 59
Study 9931796 — intervention group
Group type: COMPARATOR
Intervention: Control group (no plasmapheresis)
Number of subjects: 59
Study 9931796 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmapheresis combined with CVVHF
Number of subjects: 59
Study 7987884 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-AMI patients
Number of subjects: 3298
Study 7987884 — intervention group
Group type: EXPERIMENTAL
Intervention: AMI patients
Number of subjects: 3298
Study 2697693 — intervention group
Group type: EXPERIMENTAL
Intervention: Ayurvedic preparation (Aegle marmelos correa plus Bacopa monniere Linn)
Number of subjects: 169
Study 2697693 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy (clidinium bromide, chlordiazepoxide and isaphaghulla)
Number of subjects: 169
Study 2697693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study 2697693 — intervention group
Group type: EXPERIMENTAL
Intervention: Ayurvedic preparation
Number of subjects: 169
Study 2697693 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy
Number of subjects: 169
Study 2697693 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy and Ayurvedic therapy
Number of subjects: 169
Study 2697693 — intervention group
Group type: EXPERIMENTAL
Intervention: Both forms of therapy (Ayurvedic and Standard)
Number of subjects: 169
Study 961187 — intervention group
Group type: EXPERIMENTAL
Intervention: Solcoseryl
Number of subjects: 31
Study 961187 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 7410127 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Methotrexate (25 mg every third day for 5 doses) followed by definitive radiotherapy
Number of subjects: 638
Study 7410127 — intervention group
Group type: COMPARATOR
Intervention: Definitive radiotherapy alone
Number of subjects: 638
Study 31846923 — intervention group
Group type: EXPERIMENTAL
Intervention: Epley maneuver bilaterally
Number of subjects: 50
Study 31846923 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 50
Study 29222574 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised hearing aid user guide and video
Number of subjects: 30
Study 29222574 — intervention group
Group type: COMPARATOR
Intervention: Original hearing aid user guide
Number of subjects: 30
Study 26936776 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate treatment for 6 weeks
Number of subjects: 40
Study 26936776 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 6 weeks
Number of subjects: 40
Study 25208127 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-(1-7) infusion (0.27, 0.9, and 2.7 ng/kg per min)
Number of subjects: 0
Study 25208127 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-(1-7) infusion
Number of subjects: 0
Study 21822162 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ) 70 mg daily (35 mg × 2)
Number of subjects: 1086
Study 21822162 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1086
Study 21822162 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ)
Number of subjects: 1086
Study 18547450 — intervention group
Group type: EXPERIMENTAL
Intervention: Web‐PDHQ
Number of subjects: 218
Study 18547450 — intervention group
Group type: COMPARATOR
Intervention: Paper‐DHQ
Number of subjects: 218
Study 17894671 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 0
Study 14990543 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard information pack
Number of subjects: 100
Study 14990543 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra information leaflet about twin pregnancy
Number of subjects: 100
Study 14990543 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional discussion session
Number of subjects: 100
Study 14990543 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed charge for all fresh and frozen embryo transfers
Number of subjects: 100
Study 12502276 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping Power intervention
Number of subjects: 0
Study 12502276 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal intervention
Number of subjects: 0
Study 12502276 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Coping Power plus universal intervention
Number of subjects: 0
Study 12502276 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 9675609 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplement (20 ml/day)
Number of subjects: 57
Study 9675609 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean phosphatidylcholine (PC) (25 g/day)
Number of subjects: 57
Study 9675609 — intervention group
Group type: COMPARATOR
Intervention: No supplementation (control group)
Number of subjects: 57
Study 8008712 — intervention group
Group type: EXPERIMENTAL
Intervention: Small intestinal infusion (SI) of benazepril hydrochloride (20 mg)
Number of subjects: 13
Study 8008712 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonic infusion (COLON) of benazepril hydrochloride (20 mg)
Number of subjects: 13
Study 8008712 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bolus solution (ORAL) of benazepril hydrochloride (20 mg)
Number of subjects: 13
Study 8008712 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of metabolite-to-drug AUC ratios
Number of subjects: 13
Study 2481692 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran 40
Number of subjects: 40
Study 2481692 — intervention group
Group type: COMPARATOR
Intervention: Control (no Dextran 40)
Number of subjects: 40
Study 1054636 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-curing resin
Number of subjects: 50
Study 1054636 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-curing resin
Number of subjects: 50
Study 1054636 — intervention group
Group type: COMPARATOR
Intervention: Isolation with alginate film or tinfoil
Number of subjects: 50
Study 1054636 — intervention group
Group type: EXPERIMENTAL
Intervention: Roughness of the surface
Number of subjects: 50
Study 31233326 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 sessions of a brief psychological intervention designed to improve the ability to tolerate uncertainty (n = 23)
Number of subjects: 48
Study 31233326 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU; n = 25)
Number of subjects: 48
Study 27576020 — intervention group
Group type: EXPERIMENTAL
Intervention: Lift-off test
Number of subjects: 24
Study 27576020 — intervention group
Group type: EXPERIMENTAL
Intervention: Jobe test
Number of subjects: 24
Study 26035087 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing therapy with instructions to raise pCO2
Number of subjects: 0
Study 26035087 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing therapy with instructions to lower pCO2
Number of subjects: 0
Study 23471273 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (walking) training
Number of subjects: 64
Study 23471273 — intervention group
Group type: COMPARATOR
Intervention: Massage to the affected side
Number of subjects: 64
Study 21723534 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher treatment expectations
Number of subjects: 49
Study 21723534 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent expectations
Number of subjects: 49
Study 21723534 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist expectations
Number of subjects: 49
Study 21723534 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline depressive symptoms, child/parent-rated functional impairment, externalizing behavior problems, number of comorbid psychiatric disorders, lower perception of control
Number of subjects: 49
Study 21723534 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment OCD severity and prior treatment history
Number of subjects: 49
Study 18807252 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention (interactive educational meeting plus feedback on medication)
Number of subjects: 166
Study 18807252 — intervention group
Group type: COMPARATOR
Intervention: Single intervention (interactive educational meeting only)
Number of subjects: 166
Study 18807252 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 166
Study 16683061 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg bupropion
Number of subjects: 105
Study 16683061 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg sertraline
Number of subjects: 105
Study 16683061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 15282836 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Therapeutic Community (MTC)
Number of subjects: 0
Study 15282836 — intervention group
Group type: EXPERIMENTAL
Intervention: MTC + aftercare
Number of subjects: 0
Study 15282836 — intervention group
Group type: COMPARATOR
Intervention: Mental Health (MH)
Number of subjects: 0
Study 11394461 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved patient-handling technique with existing equipment
Number of subjects: 0
Study 11394461 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of additional mechanical and other assistive equipment
Number of subjects: 0
Study 11394461 — intervention group
Group type: COMPARATOR
Intervention: Education and technique training alone
Number of subjects: 0
Study 9599741 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic machine for enuresis type I
Number of subjects: 9
Study 9599741 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine for enuresis type IIa
Number of subjects: 9
Study 9599741 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin hydrochloride for enuresis type IIb
Number of subjects: 9
Study 7718029 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose ascorbate supplementation (4.5 g/day)
Number of subjects: 44
Study 7718029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 2530713 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective thromboxane receptor antagonist
Number of subjects: 0
Study 2530713 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 0
Study 782997 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical pharyngeal anesthesia with lidocaine
Number of subjects: 111
Study 782997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 31364497 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical compression stockings with integrated skin care (MCS-SC)
Number of subjects: 50
Study 31364497 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical compression stockings (MCS)
Number of subjects: 50
Study 31364497 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MCS and MCS-SC
Number of subjects: 50
Study 28839340 — intervention group
Group type: EXPERIMENTAL
Intervention: VBZ 80 mg
Number of subjects: 205
Study 28839340 — intervention group
Group type: EXPERIMENTAL
Intervention: VBZ 40 mg
Number of subjects: 205
Study 28839340 — intervention group
Group type: COMPARATOR
Intervention: PBO
Number of subjects: 205
Study 25961431 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 450
Study 24020450 — intervention group
Group type: EXPERIMENTAL
Intervention: IVR calls from weeks 13 to 52
Number of subjects: 101
Study 24020450 — intervention group
Group type: COMPARATOR
Intervention: No IVR
Number of subjects: 101
Study 24020450 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline and 9 IVR calls
Number of subjects: 101
Study 21511217 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive cilostazol (triple group; n = 64)
Number of subjects: 126
Study 21511217 — intervention group
Group type: COMPARATOR
Intervention: High maintenance-dose clopidogrel (high-MD group; n = 62)
Number of subjects: 126
Study 19967584 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex set training
Number of subjects: 15
Study 19967584 — intervention group
Group type: COMPARATOR
Intervention: Traditional set training
Number of subjects: 15
Study 17257284 — intervention group
Group type: EXPERIMENTAL
Intervention: IFG-lower (5.6-6.0 mmol/l)
Number of subjects: 1040
Study 17257284 — intervention group
Group type: EXPERIMENTAL
Intervention: IFG-original (6.1-6.9 mmol/l)
Number of subjects: 1040
Study 17257284 — intervention group
Group type: EXPERIMENTAL
Intervention: All-IFG (5.6-6.9 mmol/l)
Number of subjects: 1040
Study 17257284 — intervention group
Group type: COMPARATOR
Intervention: Normoglycaemia (< 5.6 mmol/l)
Number of subjects: 1040
Study 15480538 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet (30% protein, 40% carbohydrate)
Number of subjects: 66
Study 15480538 — intervention group
Group type: COMPARATOR
Intervention: Low-protein diet (15% protein, 55% carbohydrate)
Number of subjects: 66
Study 15480538 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 66
Study 15480538 — intervention group
Group type: COMPARATOR
Intervention: Low-protein diet
Number of subjects: 66
Study 15480538 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet
Number of subjects: 66
Study 11316388 — intervention group
Group type: EXPERIMENTAL
Intervention: Catholics and other Protestants (Anglicans and Baptists)
Number of subjects: 600
Study 11316388 — intervention group
Group type: EXPERIMENTAL
Intervention: Stronger religious belief
Number of subjects: 600
Study 11316388 — intervention group
Group type: COMPARATOR
Intervention: Evangelical Churches of West Africa (ECWA)
Number of subjects: 600
Study 9009873 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategy instruction
Number of subjects: 47
Study 9009873 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategy instruction plus goal setting
Number of subjects: 47
Study 9009873 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategy instruction plus self-instruction
Number of subjects: 47
Study 9009873 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategy instruction plus goal setting and self-instruction
Number of subjects: 47
Study 9009873 — intervention group
Group type: COMPARATOR
Intervention: Social comparison group of normally achieving students
Number of subjects: 47
Study 8274782 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone acetonide (TA) cream 0.1%
Number of subjects: 18
Study 8274782 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide plus retinoic acid (TARA) cream 0.1% plus 0.025%
Number of subjects: 18
Study 3116836 — intervention group
Group type: EXPERIMENTAL
Intervention: Unflavored yogurt
Number of subjects: 9
Study 3116836 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavored yogurt
Number of subjects: 9
Study 3116836 — intervention group
Group type: EXPERIMENTAL
Intervention: Frozen yogurt with high beta-gal
Number of subjects: 9
Study 3116836 — intervention group
Group type: EXPERIMENTAL
Intervention: Frozen yogurt (commercial procedures)
Number of subjects: 9
Study 3116836 — intervention group
Group type: COMPARATOR
Intervention: Milk, ice milk, ice cream, frozen yogurts (without cultures)
Number of subjects: 9
Study 29502974 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen
Number of subjects: 90
Study 29502974 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh Frozen Plasma (FFP)
Number of subjects: 90
Study 29502974 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 90
Study 26556618 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 1 µg/kg (medical patients) or 1.5 µg/kg (surgical patients) administered 10 min before turning
Number of subjects: 75
Study 26556618 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered 10 min before turning
Number of subjects: 75
Study 26556618 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl and Placebo
Number of subjects: 75
Study 25486674 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention combining assessment of cigarette dependence and problematic cannabis use with personalized, normative feedback
Number of subjects: 325
Study 25486674 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention based on principles of motivational interviewing
Number of subjects: 325
Study 25486674 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducational control group providing information on tobacco, cannabis, and co-use
Number of subjects: 325
Study 25486674 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions combined
Number of subjects: 325
Study 22819642 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-incision laparoscopic cholecystectomy (SI)
Number of subjects: 79
Study 22819642 — intervention group
Group type: COMPARATOR
Intervention: Multiple-incision laparoscopic cholecystectomy (MI)
Number of subjects: 79
Study 20459856 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg aspirin within 1.5 hours after start of thrombolysis
Number of subjects: 0
Study 20459856 — intervention group
Group type: COMPARATOR
Intervention: Standard care (antiplatelet therapy after 24 hours)
Number of subjects: 0
Study 18753120 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg daily for 48 weeks)
Number of subjects: 64
Study 18753120 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg daily for 48 weeks)
Number of subjects: 64
Study 18753120 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone plus Pravastatin (48 weeks)
Number of subjects: 64
Study 18753120 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH; 2 mg for 12 weeks)
Number of subjects: 64
Study 18753120 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) combined with Rosiglitazone
Number of subjects: 64
Study 15647414 — intervention group
Group type: COMPARATOR
Intervention: Indinavir/ritonavir with breakfast (reference regimen B)
Number of subjects: 8
Study 15647414 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine enteric‐coated + indinavir/ritonavir 2 hours after breakfast (test regimen C)
Number of subjects: 8
Study 15647414 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine enteric‐coated + indinavir/ritonavir with breakfast (test regimen D)
Number of subjects: 8
Study 15647414 — intervention group
Group type: COMPARATOR
Intervention: Didanosine enteric‐coated 400 mg once daily (reference regimen A)
Number of subjects: 8
Study 14610139 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 MU botulinum toxin A (BTX‐A)
Number of subjects: 32
Study 14610139 — intervention group
Group type: EXPERIMENTAL
Intervention: 37.5 MU botulinum toxin A (BTX‐A)
Number of subjects: 32
Study 14610139 — intervention group
Group type: EXPERIMENTAL
Intervention: 18.75 MU botulinum toxin A (BTX‐A)
Number of subjects: 32
Study 14610139 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 32
Study 10227447 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified FEC regimen (5-fluorouracil 600 mg/m2, epirubicin 60 mg/m2, cyclophosphamide 600 mg/m2 for two courses, followed by a modified third course with a dose of 1200 mg/m2) plus G-CSF (filgrastim) at 5 mg/kg.
Number of subjects: 50
Study 8705641 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 43
Study 8705641 — intervention group
Group type: COMPARATOR
Intervention: Positive Control
Number of subjects: 43
Study 8705641 — intervention group
Group type: COMPARATOR
Intervention: Negative Control
Number of subjects: 43
Study 1591822 — intervention group
Group type: EXPERIMENTAL
Intervention: Type Ia antiarrhythmic agents (quinidine, procainamide, disopyramide)
Number of subjects: 1567
Study 1591822 — intervention group
Group type: COMPARATOR
Intervention: Not receiving type Ia antiarrhythmic agents
Number of subjects: 1567
Study 3918450 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin rectal suppository (100 mg)
Number of subjects: 52
Study 3918450 — intervention group
Group type: COMPARATOR
Intervention: Control group (no premedication)
Number of subjects: 52
Study 31465750 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider-facilitated, patient-centered educational intervention
Number of subjects: 363
Study 31465750 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 363
Study 29157624 — intervention group
Group type: EXPERIMENTAL
Intervention: VAC-J strategy
Number of subjects: 25
Study 29157624 — intervention group
Group type: COMPARATOR
Intervention: VAC strategy
Number of subjects: 25
Study 27670864 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Thai massage (TTM)
Number of subjects: 50
Study 27670864 — intervention group
Group type: COMPARATOR
Intervention: Control (sham microwave diathermy)
Number of subjects: 50
Study 25912765 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemon detox diet (Lemon-D)
Number of subjects: 84
Study 25912765 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive-C (pair-fed placebo diet)
Number of subjects: 84
Study 25912765 — intervention group
Group type: COMPARATOR
Intervention: Normal-C (control group without diet restriction)
Number of subjects: 84
Study 23747051 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel+oxaliplatin (DOCOX)
Number of subjects: 150